The researchers found that socioeconomic status likely drives survival disparities between Hispanic patients and non-Hispanic whites (NHWs). They also found that, while both underserved populations, Hispanics and non-Hispanic blacks have different survival outcomes compared with NHWs.
Having a lower socioeconomic status (SES) drives disparities in survival outcomes for Hispanic patients with multiple myeloma, indicate new study findings.
Previous research has indicated that racial/ethnic minorities, including Hispanics and non-Hispanic blacks (NHBs), are disproportionately affected by low SES and are less likely to receive novel treatments. Research has also suggested that addressing this disparity could help improve outcomes. Data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database have showed that when treated similarly, NHB patients have significantly improved survival compared with non-Hispanic white (NHW) patients.
With similar insights lacking for Hispanics, researchers leveraged data from the same database, finding that SES likely drives survival disparities between Hispanic patients and NHWs. They also found that, while both underserved populations, Hispanics and NHBs have different survival outcomes compared with NHWs.
“Even though Hispanics and NHBs demonstrate similar and greater social and health challenges than NHWs at diagnosis, the survival disparities between these two underserved populations and NHWs are markedly different,” wrote the group. “When treated similarly, Hispanics and NHWs have comparable overall survival while NHBs have significantly longer survival than NHWs. In addition, among patients with low SES, NHBs have better survival than demographics-matched Hispanics. These findings indicate NHBs may harbor a more indolent disease subtype than other racial/ethnic groups.”
When determining differences in survival patterns between Hispanic patients and NHW patients, the researchers relied on SEER data from nearly 1600 Hispanics and over 20,000 NHWs, finding that Hispanics were more than twice as likely to have low SES (52.6% vs 23.1%).
Compared with demographics-matched NHWs, Hispanics had significantly worse median survival (30 vs 37 months) and 5-year survival rates (absolute difference, 3.6%). However, when they adjusted for SES, the differences were no longer significant (30 vs 32 months and absolute difference 2.2%, respectively). The group also found that when adjusting for demographic variables, being of Hispanic ethnicity was associated with increased risk of mortality but the association no longer remained when adjusting for SES, presentation, or treatment factors.
Stratification analyses showed that even if both Hispanics and NHWs were at a low SES, Hispanic patients still had an 18% increased risk of all-cause mortality compared with demographic-controlled NHWs.
“These results highlight the need to better understand factors beyond SES that impact MM survival disparities,” commented the researchers. “However, limited by the large number of missing values in disease-specific mortality, we were not able to assess MM-specific mortality to further examine whether comorbidities and treatments also impact MM-specific mortality. Of note, both comorbidities and treatment are important modifiable factors that may be affected by SES, providing us opportunities to eliminate these disparities.”
Reference
Buradagunta C, Garacci Z, D’Souza A, et al. Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer J. Published online May 25, 2022. doi:10.1038/s41408-022-00681-x
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Fracture Risk Lowest for Alendronate, Pamidronate Use During MM Treatment
March 21st 2024In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from facilitating jaw degradation and reducing vertebral fracture risk among patients being treated for multiple myeloma.
Read More
Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma
February 23rd 2024The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.
Read More
Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM
February 15th 2024The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.
Read More
Disability Degree, Home Health Use May Signal Need for Patient Support in MM
February 7th 2024Clinical investigators evaluated the impact of home health services on disability status and receipt of treatment among adults 66 years and older with a new diagnosis of multiple myeloma (MM).
Read More